clinical trial · NCT04076579
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
University of Michigan Rogel Cancer Center·phase2·completed·n = 29
SarcomaSarcoma MetastaticOlaparibTrabectedin
brief summary
This phase II trial studies how well trabectedin and olaparib work in treating patients with sarcoma that cannot be removed by surgery or has spread to other places in the body. Drugs used in chemotherapy, such as trabectedin, work in different ways to stop the growth of tumor cells, either by killing cells, stopping them from dividing or stopping them from spreading. Olaparib may stop the growth of tumor cells by blocking pathways responsible for repairing damaged cells. Giving trabectedin and olaparib may shrink or stop the tumor from growing.
started
Mar 17, 2020
primary completion
Jan 30, 2023
completion
Sep 26, 2024
last updated
Aug 29, 2025
official title
Phase II Multi-Center Trial of Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol